hepatoАнналы хирургической гепатологииAnnaly khirurgicheskoy gepatologii = Annals of HPB Surgery1995-54642408-9524НЭИКОН ИСП10.16931/1995-5464.2019365-72hepato-489Research ArticleОНКОЛОГИЧЕСКИЙ КОНСИЛИУМ ПРИ РАКЕ ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫCANCER COUNCIL FOR PANCREATIC CANCERРоль системной терапии при локализованном раке поджелудочной железы (обзор литературы)The role of systemic therapy in localized pancreatic cancer (review)https://orcid.org/0000-0003-4848-6938ЖуковаЛ. Г.ZhukovaL. G.

Жукова Людмила Григорьевна – доктор мед. наук, профессор РАН, заместитель директора по онкологии 

111123, Москва, шоссе Энтузиастов, д. 86. Тел.: 8-495-304-30-35, доб. 1292. E-mail: l.zhukova@mknc.ru

Lyudmila G. Zhukova – Doct. of Sci. (Med.), Professor of RAS, Deputy Director for Oncology

Loginov Moscow Clinical Scientific Center of Moscow Department of Healthcare; 86, Enthusiastov shosse, 111123, Moscow. Phone: 8-495-304-30-35, доб. 1292

zhukova.lyudmila008@mail.ruhttps://orcid.org/0000-0002-0616-5477ГречухинаК. С.GrechukhinaK. S.

Гречухина Катерина Сергеевна – клинический ординатор отделения химиотерапии

Katerina S. Grechukhina – Resident of the Chemotherapy Department

kbardovskaya@gmail.comhttps://orcid.org/0000-0001-8887-2660СмолинС. А.SmolinS. A.

Смолин Сергей Алексеевич – клинический ординатор отделения химиотерапии

Sergey A. Smolin – Resident of the Chemotherapy Department

hsifdaeh@gmail.comhttps://orcid.org/0000-0002-0144-5656БамматовБ. И.BammatovB. I.

Бамматов Басир Идрисович – клинический ординатор отделения химиотерапии

Basir I. Bammatov – Resident of the Chemotherapy Department

bammatovb@yahoo.comГБУЗ «Московский клинический научный центр им. А.С. Логинова» ДЗМРоссияLoginov Moscow Clinical Scientific Center of Moscow Department of HealthcareRussian Federation2019210820192436572Copyright © Жукова Л.Г., Гречухина К.С., Смолин С.А., Бамматов Б.И., 20192019Жукова Л.Г., Гречухина К.С., Смолин С.А., Бамматов Б.И.Zhukova L.G., Grechukhina K.S., Smolin S.A., Bammatov B.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://hepato.elpub.ru/jour/article/view/489

Несмотря на все достижения современной клинической и хирургической онкологии, результаты лечения локализованного (раннего) рака поджелудочной железы назвать удовлетворительными сложно. Тем не менее определенных успехов все же удалось добиться и у этой прогностически крайне неблагоприятной группы больных. В статье рассмотрена эволюция системной лекарственной терапии, а также новые концепции в лечении погранично-резектабельного и резектабельного рака поджелудочной железы. Проводимая противоопухолевая терапия позволила значимо улучшить результаты лечения пациентов, при этом обладая приемлемым профилем токсичности. Однако, несмотря на достигнутые результаты, необходимы дальнейшие исследования для повышения эффективности лечения.

The results of treatment of localized (early) pancreatic cancer are unsatisfactory despite all achievements of modern clinical and surgical oncology. Nevertheless, certain success was achieved even in these extremely unfavorable patients regarding their prognosis. The authors analyzed evolution of adjuvant therapy, as well as new concepts in the treatment of borderline resectable and resectable pancreatic cancer. Modern anticancer therapy with acceptable toxicity profile significantly improved the outcomes. However, further research is needed to improve the effectiveness of treatment despite favorable current results.

поджелудочная железаракадъювантная терапиянеоадъювантная терапиярезектабельностьотдаленные результатывыживаемостьpancreascanceradjuvant therapyneoadjuvant therapyresectabilitylong-term resultssurvivalReferencesNeoptolemos J.P., Dunn J.A., Stocken D.D., Almond J., Link K., Beger H., Bassi C., Falconi M., Pederzoli P., Dervenis C., Fernandez-Cruz L., Lacaine F., Pap A., Spooner D., Kerr D.J., Friess H., Büchler M.W. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001; 358 (9293): 1576–1585. http://doi.org/10.1016/S0140-6736(01)06651-X.Neoptolemos J.P., Dunn J.A., Stocken D.D., Almond J., Link K., Beger H., Bassi C., Falconi M., Pederzoli P., Dervenis C., Fernandez-Cruz .L, Lacaine F., Pap A., Spooner D., Kerr D.J., Friess H., Büchler M.W. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576 – 1585. Doi.org/10.1016/S0140-6736(01)06651-X.Crane C.H., Ben-Josef E., Small W. Chemotherapy for pancreatic cancer. N. Engl. J. Med. 2004; 350 (26): 2713–2715. http://doi.org/10.1056/NEJM200406243502617.Crane C.H., Ben-Josef E., Small W. Chemotherapy for pancreatic cancer. N. Engl. J. Med. 2004;350(26):2713-2715. DOI: 10.1056/NEJM200406243502617.Koshy M.C., Landry J.C., Cavanaugh S.X., Fuller C.D., Willett C.G., Abrams R.A., Hoffman J.P., Thomas C.R. Jr. A challenge to the therapeutic nihilism of ESPAC-1. Int. J. Radiat. Oncol. Biol. Phys. 2005; 61 (4): 965–966. http://doi.org/10.1016/j.ijrobp.2004.11.018.Koshy M.C., Landry J.C., Cavanaugh S.X., Fuller C.D., Willett C.G., Abrams R.A., Hoffman J.P., Thomas C.R. Jr. A challenge to the therapeutic nihilism of ESPAC-1. Int. J.Radiat. Oncol. Biol. Phys. 2005;61(4):965-966. DOI: 10.1016/j.ijrobp.2004.11.018.Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., Schramm H., Fahlke J., Zuelke C., Burkart C., Gutberlet K., Kettner E., Schmalenberg H., WeigangKoehler K., Bechstein W.O., Niedergethmann M., SchmidtWolf I., Roll L., Doerken B., Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297 (3): 267–277. http://doi.org/10.1001/jama.297.3.267.Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., Schramm H., Fahlke J., Zuelke C., Burkart C., Gutberlet K., Kettner E., Schmalenberg H., Weigang-Koehler K., Bechstein W.O., Niedergethmann M., Schmidt-Wolf I., Roll L., Doerken B., Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267-277. DOI: 10.1001/jama.297.3.267.Oettle H.I., Neuhaus P., Hochhaus A., Hartmann J.T., Gellert K., Ridwelski K., Niedergethmann M., Zülke C., Fahlke J., Arning M.B., Sinn M., Hinke A., Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310 (14): 1473–1481. http://doi.org/10.1001/jama.2013.279201.Oettle H.I., Neuhaus P., Hochhaus A., Hartmann J.T., Gellert K., Ridwelski K., Niedergethmann M., Zülke C., Fahlke J., Arning M.B., Sinn M., Hinke A., Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013;310(14):1473-1481. DOI:10.1001/jama.2013.279201.Neoptolemos J.P., Palmer D.H., Ghaneh P., Psarelli E.E., Valle J.W., Halloran C.M., Faluyi O., O'Reilly D.A., Cunningham D., Wadsley J., Darby S., Meyer T., Gillmore R., Anthoney A., Lind P., Glimelius B., Falk S., Izbicki J.R., Middleton G.W., Cummins S., Ross P.J., Wasan H., McDonald A., Crosby T., Ma Y.T., Patel K., Sherriff D., Soomal R., Borg D., Sothi S., Hammel P., Hackert T., Jackson R., Büchler M.W. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, openlabel, randomised, phase 3 trial. Lancet. 2017; 389 (10073): 1011–1024. http://doi.org/10.1016/S0140-6736(16)32409-6.Neoptolemos J.P., Palmer D.H., Ghaneh P., Psarelli E.E., Valle J.W., Halloran C.M., Faluyi O., O'Reilly D.A., Cunningham D., Wadsley J., Darby S., Meyer T., Gillmore R., Anthoney A., Lind P., Glimelius B., Falk S., Izbicki J.R., Middleton G.W., Cummins S., Ross P.J., Wasan H., McDonald A., Crosby T., Ma Y.T., Patel K., Sherriff D., Soomal R., Borg D., Sothi S., Hammel P., Hackert T., Jackson R., Büchler M.W. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011-1024. Doi: 10.1016/S0140-6736(16)32409-6.Sinn M., Bahra M., Liersch T., Gellert K., Messmann H., Bechstein W., Waldschmidt D., Jacobasch L., Wilhelm M., Rau B.M., Grützmann R., Weinmann A., Maschmeyer G., Pelzer U., Stieler J.M., Striefler J.K., Ghadimi M., Bischoff S., Dörken B., Oettle H., Riess H. CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks – a prospective randomized phase III study. J. Clin. Oncol. 2017; 35 (29): 3330–3337. http://doi.org/10.1200/JCO.2017.72.6463.Sinn M., Bahra M., Liersch T., Gellert K., Messmann H., Bechstein W., Waldschmidt D., Jacobasch L., Wilhelm M., Rau B.M., Grützmann R., Weinmann A., Maschmeyer G., Pelzer U., Stieler J.M., Striefler J.K., Ghadimi M., Bischoff S., Dörken B., Oettle H., Riess H. CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks--A prospective randomized phase III study. J. Clin. Oncol. 2017;35(29):3330-3337.Doi: 10.1200/JCO.2017.72.6463.Uesaka K., Boku N., Fukutomi A., Okamura Y., Konishi M., Matsumoto I., Kaneoka Y., Shimizu Y., Nakamori S., Sakamoto H., Morinaga S., Kainuma O., Imai K., Sata N., Hishinuma S., Ojima H., Yamaguchi R., Hirano S., Sudo T., Ohashi Y. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016; 388 (10041): 248–257. http://doi.org/10.1016/S0140-6736(16)30583-9.Uesaka K., Boku N., Fukutomi A., Okamura Y., Konishi M., Matsumoto I., Kaneoka Y., Shimizu Y., Nakamori S., Sakamoto H., Morinaga S., Kainuma O., Imai K., Sata N., Hishinuma S., Ojima H., Yamaguchi R., Hirano S., Sudo T., Ohashi Y. Adjuvant chemotherapy of S- 1 versus gemcitabine for resected pancreatic cancer: a phase 3, open- label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248-257. Doi: 10.1016/S0140-6736(16)30583-9. .Thierry C., Pascal H., Mohamed H., Meher B.A., Alice C.W., Jean-Luc R., Laurence C., Eric F., Pascal A., James J.B., Thierry L., Eric A., Roger F., Marc Y., Julien V., Alain S., Claire J.Z., Patrick R.T., Florence C., Jean-Baptiste B. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J. Clin. Oncol. 2018; 36: LBA4001-LBA4001.Thierry C,, Pascal H., Mohamed H., Meher B.A., Alice C.W., Jean-Luc R., Laurence C., Eric F., Pascal A., James J.B., Thierry L., Eric A., Roger F., Marc Y., Julien V., Alain S., Claire J.Z., Patrick R.T., Florence C., Jean-Baptiste B. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J. Clin. Oncol. 2018;36:LBA4001-LBA4001.Gilbert J.W., Wolpin B., Clancy T., Wang J., Mamon H., Shinagare A.B., Jagannathan J., Rosenthal M. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Ann. Oncol. 2017; 28 (9): 2067–2076. http://doi.org/10.1093/annonc/mdx180.Gilbert J.W., Wolpin B., Clancy T., Wang J., Mamon H., Shinagare A.B., Jagannathan J., Rosenthal M. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Ann. Oncol. 2017;28(9):2067–2076. Doi.org/10.1093/annonc/mdx180.Massucco P., Capussotti L., Magnino A., Sperti E., Gatti M., Muratore A., Sgotto E., Gabriele P., Aglietta M. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann. Surg. Oncol. 2006; 13 (9): 1201–1208. http://doi.org/10.1245/s10434-006-9032-x.Massucco P., Capussotti L., Magnino A., Sperti E., Gatti M., Muratore A., Sgotto E., Gabriele P., Aglietta M. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann. Surg..Oncol. 2006 Sep;13(9):1201-8. DOI: 10.1245/s10434-006-9032-x.Quiros R.M., Brown K.M., Hoffman J.P. Neoadjuvant therapy in pancreatic cancer. Cancer Invest. 2007; 25 (4): 267–273. http://doi.org/10.1080/07357900701206356.Quiros R.M., Brown K.M., Hoffman J.P. Neoadjuvant therapy in pancreatic cancer. Cancer Invest. 2007;25(4):267-273.DOI: 10.1080/07357900701206356.Versteijne E., van Eijck C.H., Punt C.J., Suker M., Zwinderman A.H., Dohmen M.A., Groothuis K.B., Busch O.R., Besselink M.G., de Hingh I.H., Ten Tije A.J., Patijn G.A., Bonsing B.A., de Vos-Geelen J., Klaase J.M., Festen S., Boerma D., Erdmann J.I., Molenaar I.Q., van der Harst E., van der Kolk M.B., Rasch C.R., van Tienhoven G. Dutch Pancreatic Cancer Group (DPCG). Preoperative chemo radiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. J. Clin. Oncol. 2018; 36 (suppl.; abstr. LBA4002).Versteijne E., van Eijck C.H., Punt C.J., Suker M., Zwinderman A.H., Dohmen M.A., Groothuis K.B., Busch O.R., Besselink M.G., de Hingh I.H., Ten Tije A.J., Patijn G.A., Bonsing B.A., de Vos-Geelen J., Klaase J.M., Festen S., Boerma D., Erdmann J.I., Molenaar I.Q., van der Harst E., van der Kolk M.B., Rasch C.R., van Tienhoven G. Dutch Pancreatic Cancer Group (DPCG). Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectablepancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. J. Clin. Oncol. 2018;36 (suppl; abstr LBA4002)Truty M.J., Kendrick M.L., Nagorney D.M., Smoot R.L., Cleary S.P., Graham R.P., Goenka A.H., Hallemeier C.L., Haddock M.G., Harmsen W.S., Mahipal A., McWilliams R.R., Halfdanarson T.R., Grothey A.F. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann. Surg. 2019. http://doi.org/10.1097/SLA.0000000000003284. [Epub ahead of print].Truty M.J., Kendrick M.L., Nagorney D.M., Smoot R.L., Cleary S.P., Graham R.P., Goenka A.H., Hallemeier C.L., Haddock M.G., Harmsen W.S., Mahipal A., McWilliams R.R., Halfdanarson T.R., Grothey A.F. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Ann. Surg. 2019 . Doi: 10.1097/SLA.0000000000003284. [Epub ahead of print].Xu J.Z., Wang W.Q., Zhang S.R., Xu H.X., Wu C.T., Qi Z.H., Gao H.L., Li S., Ni Q.X., Yu X.J., Liu L. Neoadjuvant therapy is essential for resectable pancreatic cancer. Curr. Med. Chem. 2018; 25: 1. http://doi.org/10.2174/09298673256661804131017 22. [Epub ahead of print].Xu J.Z., Wang W.Q., Zhang S.R., Xu H.X., Wu C.T., Qi Z.H., Gao H.L., Li S., Ni Q.X., Yu X.J., Liu L. Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Curr. Med. Chem. 2018; 25:1. Doi: 10.2174/0929867325666180413101722. [Epub ahead of print].Mokdad A., Minter R., Zhu H. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J. Clin. Oncol. 2017; 35 (5): 515–522. http://doi.org/10.1200/JCO.2016.68.5081.Mokdad A., Minter R., Zhu H. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable PancreaticCancer: A Propensity Score Matched Analysis. J. Clin. Oncol. 2017;35(5):515-522. Doi: 10.1200/JCO.2016.68.5081.Reni M., Balzano G., Zanon S., Zerbi A., Rimassa L., Castoldi R., Pinelli D., Mosconi S., Doglioni C., Chiaravalli M., Pircher C., Arcidiacono P.G., Torri V., Maggiora P., Ceraulo D., Falconi M., Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. Lancet Gastroenterol. Hepatol. 2018; 3 (6): 413–423. http://doi.org/10.1016/S2468-1253(18)30081-5.Reni M., Balzano G., Zanon S., Zerbi A., Rimassa L., Castoldi R., Pinelli D., Mosconi S., Doglioni C., Chiaravalli M., Pircher C., Arcidiacono P.G., Torri V., Maggiora P., Ceraulo D., Falconi M., Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. Lancet Gastroenterol. Hepatol. 2018;3(6):413-423. Doi: 10.1016/S2468-1253(18)30081-5.Barenboim A., Lahat G., Geva R., Nachmany I., Nakache R., Goykhman Y., Brazowski E., Rosen G., Isakov O., Wolf I., Klausner J.M., Lubezky N. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Eur. J. Surg. Oncol. 2018; 44 (10): 1619–1623. http://doi.org/10.1016/j.ejso.2018.07.057.Barenboim A., Lahat G., Geva R., Nachmany I., Nakache R., Goykhman Y., Brazowski E., Rosen G., Isakov O., Wolf I., Klausner J.M., Lubezky N. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Eur. J. Surg. Oncol. 2018;44(10):1619-1623. Doi: 10.1016/j.ejso.2018.07.057.Chapman B.C., Gleisner A., Rigg D., Messersmith W., Paniccia A., Meguid C., Gajdos C., McCarter M.D., Schulick R.D., Edil B.H. Perioperative and survival outcomes following neoadjuvant FOLFIRINOX versus gemcitabine abraxane in patients with pancreatic adenocarcinoma. JOP. 2018; 19 (2): 75–85. Published online 2018 Mar 30.Chapman B.C., Gleisner A., Rigg D., Messersmith W., Paniccia A., Meguid C., Gajdos C., McCarter M.D., Schulick R.D., Edil B.H. Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma. JOP. 2018;19(2):75–85. Published online 2018 Mar 30.Mokdad A.A., Minter R.M., Yopp A.C., Porembka M.R., Wang S.C., Zhu H., Augustine M.M., Mansour J.C., Choti M.A., Polanco P.M. Comparison of overall survival between preoperative chemotherapy and chemoradiotherapy for resectable pancreatic adenocarcinoma. J. Natl. Compr. Canc. Netw. 2018; 16 (12): 1468–1475. http://doi.org/10.6004/jnccn.2018.7068.Mokdad A.A., Minter R.M., Yopp A.C., Porembka M.R., Wang S.C., Zhu H., Augustine M.M., Mansour J.C., Choti M.A., Polanco P.M. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma, Journal of the National Comprehensive Cancer Network. J. Natl. Compr. Canc. Netw. 2018; 16(12): 1468-1475. Doi: 10.6004/jnccn.2018.7068.Javed A.A., Wright M.J., Siddique A., Blair A.B., Ding D., Burkhart R.A., Makary M., Cameron J.L., Narang A., Herman J., Zheng L., Laheru D., Weiss M.J., Wolfgang C., He J. Outcome of patients with borderline resectable pancreatic cancer in the contemporary era of neoadjuvant chemotherapy. J. Gastrointest. Surg. 2018; 23 (1): 112–121. http://doi.org/10.1007/s11605-018-3966-821.Javed A.A., Wright M.J., Siddique A., Blair A.B., Ding D., Burkhart R.A., Makary M., Cameron J.L., Narang A., Herman J., Zheng L., Laheru D., Weiss M.J., Wolfgang C., He J. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. J. Gastrointest. Surg. 2018;23(1):112–121. Doi:10.1007/s11605-018-3966-821.Petrucciani N., Nigri G., Debs T., Giannini G., Sborlini E., Antolino L., Aurello P., D'Angelo F., Gugenheim J., Ramacciato G. Frozen section analysis of the pancreatic margin during pancreaticoduodenectomy for cancer: Does extending the resection to obtain a secondary R0 provide a survival benefit? Results of a systematic review. Pancreatology. 2016; 16 (6): 1037–1043. http://doi.org/10.1016/j.pan.2016.09.004.Petrucciani N., Nigri G., Debs T., Giannini G., Sborlini E., Antolino L., Aurello P., D'Angelo F., Gugenheim J., Ramacciato G. Frozen section analysis of the pancreatic margin during pancreaticoduodenectomy for cancer: Does extending the resection to obtain a secondary R0 provide a survival benefit? Results of a systematic review. Pancreatology. 2016;16(6):1037-1043.Doi: 10.1016/j.pan.2016.09.004.Motoi F., Kosuge T., Ueno H., Yamaue H., Satoi S., Sho M., Honda G., Matsumoto I., Wada K., Furuse J., Matsuyama Y., Unno M. Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP). Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). J. Clin. Oncol. 2019; 37 (suppl. 4; abstr. 189).Motoi F., Kosuge T., Ueno H., Yamaue H., Satoi S., Sho M., Honda G., Matsumoto I., Wada K., Furuse J., Matsuyama Y., Unno M. Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP).. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). J. Clin. Oncol. 2019;37 (suppl.4; abstr.189).https://clinicaltrials.gov/ct2/show/NCT02839343.https://clinicaltrials.gov/ct2/show/NCT02839343Katz M.H., Shi Q., Ahmad S.A., Herman J.M., Marsh Rde W., Collisson E., Schwartz L., Frankel W., Martin R., Conway W., Truty M., Kindler H., Lowy A.M., Bekaii-Saab T., Philip P., Talamonti M., Cardin D., LoConte N., Shen P., Hoffman J.P., Venook A.P. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016; 151 (8): e161137. http://doi.org/10.1001/jamasurg.2016.1137.Katz M.H., Shi Q., Ahmad S.A., Herman J.M., Marsh Rde W., Collisson E., Schwartz L., Frankel W., Martin R., Conway W., Truty M., Kindler H., Lowy A.M., Bekaii-Saab T., Philip P., Talamonti M., Cardin D., LoConte N., Shen P., Hoffman J.P., Venook A.P. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016;151(8):e161137. Doi: 10.1001/jamasurg.2016.1137. .

The authors declare that there are no conflicts of interest present.